Resources from the same session
279MO - Three-year survival, safety and extended long-term survivor (eLTS) analysis from the phase III TOPAZ-1 study of durvalumab (D) plus chemotherapy in biliary tract cancer (BTC)
Presenter: Do-Youn Oh
Session: Mini Oral session 3
Resources:
Abstract
Slides
Webcast
280MO - CD40 agonist mitazalimab combined with mFOLFIRINOX (mFFX) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Primary analysis of the OPTIMIZE-1 phase Ib/II study
Presenter: Teresa Macarulla Mercade
Session: Mini Oral session 3
Resources:
Abstract
Slides
Webcast
Invited discussant abstracts 279MO and 280MO
Presenter: Zev Wainberg
Session: Mini Oral session 3
Resources:
Slides
Webcast
395MO - Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in advanced or metastatic esophageal squamous cell carcinoma (ESCC): PD-L1 biomarker analysis from RATIONALE-306
Presenter: Eric Raymond
Session: Mini Oral session 3
Resources:
Abstract
Slides
Webcast
396MO - Anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate (ADC) IBI343 in patients (pts) with solid tumors and gastric/gastro-esophageal junction adenocarcinoma (G/GEJ AC): A phase I study
Presenter: Jia Jenny Liu
Session: Mini Oral session 3
Resources:
Abstract
Slides
Webcast
397MO - Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in HER2-negative advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma (GC/GEJC): PD-L1 biomarker analysis from RATIONALE-305
Presenter: Markus Moehler
Session: Mini Oral session 3
Resources:
Abstract
Slides
Webcast
Invited discussant abstracts 395MO, 396MO and 397MO
Presenter: David Ilson
Session: Mini Oral session 3
Resources:
Slides
Webcast
Q&A and discussion
Session: Mini Oral session 3
Resources:
Webcast